Oral TGF-βR1 inhibitor Vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

Osteosarcoma (OS) is an aggressive malignant bone cancer, with refractory and metastatic disease remaining a significant challenge. Transforming growth factor-β1 (TGF-β) is a potent immune suppressive cytokine in OS and the TGF-β is increased in the sera of OS patients and this increase is associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Sung Hee, Myers, Jay, Tomchuck, Suzanne, Bonner, Melissa, Eid, Saada, Kingsley, Daniel, VanHeyst, Kristen, Kim, Seong-Jin, Kim, Byung-Gyu, Huang, Alex Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104208/
https://www.ncbi.nlm.nih.gov/pubmed/37066414
http://dx.doi.org/10.21203/rs.3.rs-2709282/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104208/
https://www.ncbi.nlm.nih.gov/pubmed/37066414
http://dx.doi.org/10.21203/rs.3.rs-2709282/v1

Ejemplares similares